… Chronic myeloid leukemia (… Chronic myeloid leukemia may be more difficult to differentiate
from other myeloproliferative or myelodysplastic syndromes. Patients with agnogenic myeloid …

… targeted therapies in oncology. With three successive generations of BCR/ABL1 TKIs approved
today, the majority of CML patients enjoy long term … BCR/ABL1 targeted therapies, stem …

… phase (CML-CP) the first-line treatment is based on targeted therapy with TKIs. Imatinib is
the first BCR-ABL1 TKI approved for the treatment of CML, and frontline treatment with imatinib …

… of achieving treatment-free remission after targeted therapies, we describe here the journey
of … We highlight current strategies for combination therapies aimed at eradicating the CML …

… the stage for the development of therapeutic strategies aimed specifically at inhibiting this
kinase … Cancer Center long-term experience of chronic myeloid leukemia frontline therapy with …

… Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia (Ph) …
Table 4 Ongoing clinical trials for BCR-ABL1–targeted therapies for CML in 3L + setting …

… When an international group of CML experts called attention to the high prices of TKIs,
the cost history of imatinib (the first small-molecule targeted therapy in cancer) was used to …

… Chronic myeloid leukemia (CML) is characterized by the presence of the BCR-ABL1 fusion
gene, which encodes a constitutive active tyrosine kinase considered to be the pathogenic …

… leukemia (AML) is steadily growing. The discovery of imatinib for chronic myeloid leukemia
(CML) and its remarkable results raised hopes for similar benefits of targeted therapies in …

… As the second generation TKI, Ponatinib has been indicated for patients with TKI resistant
chronic myeloid leukemia (CML) [70]. Recent results showed Ponatinib also comprises a high …